Streetbeat News

Analyst Ratings

ARWR

Analysts have provided various ratings for Arrowhead Pharma (NASDAQ:ARWR) within the last quarter, with the majority being bullish. The average 12-month price target for Arrowhead Pharma, according to 10 analysts, is $62.1, a decrease of 5.19% from the previous average price target of $65.50.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 9:00 pm

SUPN

Supernus Pharmaceuticals reported Q2 earnings per share (EPS) of $(0.02), beating the analyst consensus estimate of $(0.23) by 91.3%. However, the company's quarterly sales of $135.56 million missed the analyst consensus estimate of $144.38 million by 6.11%. This represents a 114.29% decrease in EPS and a 20.28% decrease in sales compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

August 08, 2023 | 9:00 pm

CHPT

ChargePoint Hldgs (NYSE:CHPT) has received mostly bullish ratings from analysts in the last quarter. The company has an average price target of $14.83, a decrease of 9.68% from the previous average price target of $16.42.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 9:00 pm

PAA

In the last quarter, Plains All American (NASDAQ:PAA) received 3 bullish, 1 somewhat bullish, and 1 indifferent rating from analysts. The company's average 12-month price target is $17.4, an increase of 8.75% over the past month. Analysts derive their ratings from various sources including company conference calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 9:00 pm

NXST

Over the past 3 months, 4 analysts have published their opinion on Nexstar Media Gr (NASDAQ:NXST) stock. The company has an average price target of $229.5, an increase of 6.25% from the previous average price target of $216.00. The analysts are generally bullish on the stock.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 9:00 pm

GPMT

Granite Point Mortgage (NYSE:GPMT) reported Q2 earnings of $0.20 per share, beating the analyst consensus estimate of $0.14 by 42.86%. However, this is a 9.09% decrease from the same period last year. The company also reported quarterly sales of $21.84 million, beating the analyst consensus estimate of $20.95 million by 4.25%, but this is a 0.43% decrease from the same period last year.

Portfolio Pulse from totan@benzinga.com

August 08, 2023 | 8:50 pm

MEG

Montrose Environmental Gr (NYSE:MEG) reported Q2 earnings of $0.13 per share, beating the analyst consensus estimate of $(0.29) by 144.83%. This is a 333.33% increase over earnings of $0.03 per share from the same period last year. The company also reported quarterly sales of $159.10 million, beating the analyst consensus estimate of $145.23 million by 9.55%. This is a 13.72% increase over sales of $139.91 million the same period last year.

Portfolio Pulse from totan@benzinga.com

August 08, 2023 | 8:46 pm

BABA

A significant number of bearish trades have been observed in Alibaba Group Holding's (NYSE:BABA) options, with 53% of investors showing bearish expectations. The price range targeted by these investors over the last three months is $45.0 to $270.0. The price of BABA is currently down by 2.42% at $94.22. Baird has downgraded its action to Outperform with a price target of $115, while B of A Securities maintains a Buy rating with a price target of $137.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 8:45 pm

DHI

A significant investor has taken a bearish stance on D.R. Horton (NYSE:DHI), with 53% of recent trades being bearish and 46% bullish. The total amount for puts is $463,168 and for calls is $388,700. Whales have been targeting a price range from $123.0 to $135.0 for D.R. Horton over the last 3 months. Several financial institutions have maintained or upgraded their ratings on D.R. Horton, with price targets ranging from $140 to $160.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 8:45 pm

SEER

Seer (NASDAQ:SEER) reported Q2 losses of $(0.37) per share, beating the analyst consensus estimate of $(0.39) by 5.13%. However, the company's quarterly sales of $4.01 million missed the analyst consensus estimate of $5.07 million by 20.95%. This represents a 10.69% increase over sales of $3.62 million the same period last year.

Portfolio Pulse from saritha@benzinga.com

August 08, 2023 | 8:43 pm